Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026519 | 0.92 | MEN1 (0.64) | KMT2AMEN1SCN2ANPC1RAB9A | |
| SCHEMBL6883824 | 0.89 | KMT2A (0.53) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL6886575 | 0.89 | NPC1 (0.43) | KMT2ASCN2ANPC1RAB9AAURKA | |
| SCHEMBL6885314 | 0.89 | NPC1 (0.53) | KMT2ANPC1RAB9AJAK2ALDH1A1 | |
| SCHEMBL6887573 | 0.84 | NR2E3 (0.45) | KMT2AMEN1NPC1RAB9APKM | |
| SCHEMBL6885545 | 0.83 | ABL1 (0.45) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6028312 | 0.83 | RAB9A (0.52) | NPC1RAB9ATP53SMN1; SMN2KDM4E | |
| SCHEMBL6029160 | 0.83 | PTPN1 (0.54) | NPC1RAB9ATP53SMN1; SMN2HSD17B10 | |
| SCHEMBL6028319 | 0.83 | PTPN1 (0.54) | NPC1RAB9ATP53SMN1; SMN2HSD17B10 | |
| SCHEMBL6026517 | 0.83 | MEN1 (0.52) | KMT2AMEN1SCN2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1826111-A | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS (US) | 2006-08-30 | — | — | CN | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | KMT2A 361/4885MEN1 2429/4885SCN2A 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.